Sort
15,273 grants matching “antimicrobial resistance”
Comparative Efficacy of Therapeutics for Clostridioides difficile Infection
$300,000Raquel Hontecillas · Biotherapeutics, Inc. · R43 · FY2024 · AI
Metagenomic discovery and optimization of novel endolysins targeting Gardnerella vaginalis to treat bacterial vaginosis
$300,000Oliver Wei Liu · Topaz Biosciences, Inc. · R43 · FY2024 · AI
SQ641, new drug candidate to treat NTM infections
$300,000Venkata M Reddy · Sequella, Inc. · R43 · FY2010 · AI
A broad spectrum anti-gonorrhea immunotherapeutic
$300,000Keith Wycoff · Planet Biotechnology, Inc. · R41 · FY2024 · AI
Novel Antibacterial Agents That Target DNA Replication in Mycobacterium tuberculo
$300,000Michael J Pucci · Achillion Pharmaceuticals, Inc. · R43 · FY2010 · AI
Factor H-Fc Fusion as a Pre-Exposure Prophylactic for Rickettsia Infections
$300,000Keith Wycoff · Planet Biotechnology, Inc. · R43 · FY2024 · AI
A Compliant Superhydrophobic Antimicrobial Photodynamic Therapy Bandage for the Prevention of Multidrug Resistant Wound Infections
$300,000Qianfeng Xu · Singleto2 Therapeutics, Llc · R41 · FY2024 · AI
Structure-Based Design of Sortase Inhibitors for Anti-Infective Therapy
$300,000Bing Li · Microbiotix, Inc · R43 · FY2010 · AI
Aminoglycosides with reduced ototoxicity
$300,000Dev Priya Arya · Nubad, Llc · R41 · FY2016 · AI
Anti-virulence FimH inhibitors for the treatment and prevention of UTIs
$300,000Zachary Cusumano · Fimbrion Therapeutics, Inc. · R43 · FY2014 · AI
Development, Preclinical and Preanalytical Evaluation of a Rapid Point-of-Care NAAT Device to determine Ciprofloxacin Sensitivity of Gonococci in Urogenital Samples
$300,000Gary Schoolnik · Visby Medical, Inc. · R44 · FY2019 · AI
Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection
$300,000Barbara I Kazmierczak · L2 Diagnostics, Llc · R41 · FY2016 · AI
Novel dermal templates for prevention and treatment of biofilms in cutaneous wounds
$300,000Manav Mehta · Gel4med, Inc. · R43 · FY2019 · AI
Aminoglycosides with reduced ototoxicity
$300,000Dev Priya Arya · Nubad, Llc · R41 · FY2017 · AI
Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool
$300,000Chengcang Charles Wu · Intact Genomics, Inc. · R44 · FY2019 · AI
Aminoglycosides with reduced ototoxicity via miRNA targeting
$300,000Dev Priya Arya · Nubad, Llc · R41 · FY2019 · AI
Using combinations of single-cell phenotypes for rapid antibiotic susceptibility testing
$300,000Kwangmin Son · Phast Corporation · R43 · FY2019 · AI
POINT-OF-CARE (POC) DIAGNOSTICS FOR ANTIMICROBIAL RESISTANT PATHOGENS
$300,000Jason Zhou · Zymeron Corporation · N01 · FY2022 · AI
A comprehensive next generation sequencing diagnostic tool for lung infection among hospitalized patients
$300,000Tasha E. Fingerlin · Peak Diagnostic Partners Llc · R43 · FY2022 · AI
Susceptibility Testing, Treatment Choices, and Outcomes of MDR-GNB Infections
$300,000Lisa Saiman · Columbia University Health Sciences · R01 · FY2009 · CI
Development and optimization of a nitric oxide releasing microparticle formulation for the topical treatment of chronic rhinosinusitis
$300,000Andrew R Draganski · Zylo Therapeutics, Inc. · R41 · FY2025 · AI
Development of Image Based Profiling for Antifungal Discovery
$300,000Marc Sharp · Linnaeus Bioscience, Inc. · R43 · FY2018 · AI
Development of a novel agent to treat antimicrobial resistant Neisseria gonorrhoeae
$300,000Terry Roemer · Prokaryotics, Inc. · R44 · FY2018 · AI
Therapeutic Agents Targeting Cryptococcal Infections
$300,000Dennis L Wright · Quercus Molecular Design, Llc · R41 · FY2023 · AI
Thiazolino-Pyridone Compounds as Novel Drugs for Tuberculosis
$300,000Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R43 · FY2023 · AI